Indicated for: psoriasis; vitiligo
Route of administration: oral
Substance: methoxalen (immunomodulator)
ATC: D05BA02 (Dermatologicals | Antipsoriatics for systemic use | Psoralens for systemic use)
Methoxsalen is a medication used to treat certain dermatological and skin conditions, such as severe psoriasis, vitiligo, and cutaneous T-cell lymphoma. It belongs to a class of drugs called psoralens and is used in combination with ultraviolet A (UVA) radiation therapy, known as PUVA therapy (Psoralen + UVA).
Methoxsalen works by increasing the skin's sensitivity to UVA radiation. After taking the medication, exposure to UVA light triggers a photochemical reaction that slows the growth of skin cells and reduces inflammation. This mechanism is beneficial in treating conditions characterized by excessive skin cell growth or loss of pigmentation.
The medication is available in oral capsules or topical solutions, depending on the condition being treated. In PUVA therapy, methoxsalen is administered a few hours before UVA exposure. The dosage and frequency of treatment are determined by the doctor based on the severity of the condition and the patient’s response.
Common side effects include nausea, skin redness, itching, or a burning sensation. In rare cases, more serious adverse effects such as severe sunburn, premature skin aging, or an increased risk of skin cancer may occur. It is essential for patients to avoid excessive sun exposure and use sunscreen.
Methoxsalen is contraindicated in patients with photosensitive skin disorders, skin cancer, or severe liver disease. It is important for the treatment to be conducted under the supervision of a specialist, and patients must strictly follow instructions to minimize associated risks.